We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Puts Clinical Hold on Magenta’s AML and MDS Candidate
FDA Puts Clinical Hold on Magenta’s AML and MDS Candidate
The FDA has placed a clinical hold on Magenta Therapeutics’ Investigational New Drug (IND) application for its leukemia and myelodysplastic syndrome drug candidate, MGTA-117.